Enhanced indolinone based protein kinase inhibitors
申请人:Liang Congxin
公开号:US20060287381A1
公开(公告)日:2006-12-21
Hydroxy carboxy pyrrolyl-indolinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. More particularly, alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl) amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases with respect to their corresponding beta-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl) amino alkanoic acid and amide derivatives and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
Enhanced Indolinone Based Protein Kinase Inhibitors
申请人:Liang Congxin
公开号:US20100267719A1
公开(公告)日:2010-10-21
Alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl)amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS
申请人:THE SCRIPPS RESEARCH INSTITUTE
公开号:EP1893194A1
公开(公告)日:2008-03-05
EP1893194A4
申请人:——
公开号:EP1893194A4
公开(公告)日:2009-07-01
[EN] ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE A BASE D'INDOLINONE AMELIOREE
申请人:SCRIPPS RESEARCH INST
公开号:WO2006127961A1
公开(公告)日:2006-11-30
[EN] Alpha-hydroxy- omega-(2-oxo-indolylidenemethyl-pyrrole-3'-carbonyl) amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. [FR] Selon l'invention, un acide alpha-hydroxy-oméga-(2-oxo-indolylideneméthyl-pyrrole-3'-carbonyl) amino alcanoïque et des dérivés amide présentent des propriétés médicamenteuses améliorées et inattendues en tant qu'inhibiteurs des protéines kinases et conviennent au traitement de troubles relatifs à des activités anormales de la protéine kinase, tels que le cancer.